Loading
Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.
Pazopanib is an ATP-competitive inhibitor of VEGFR1-3, PDGFR alpha and beta, KIT and FGFR that starves tumours of new blood vessels. It is the only multi-kinase inhibitor approved for soft-tissue sarcoma and is used after chemotherapy fails. In PALETTE, patients with non-adipocytic soft-tissue sarcoma after anthracycline had PFS 4.6 versus 1.6 months on placebo (HR 0.31) but no OS benefit, and the FDA approved it in April 2012; liposarcoma was excluded after poor phase 2 results. It was first approved in 2009 for advanced renal cell carcinoma, where newer combinations have largely displaced it. Liver enzyme elevation carries a boxed warning, hypertension affected 41%, fatigue 65%, and pneumothorax in about 3% is a sarcoma-specific concern; Novartis markets it. Pazopanib delays progression in sarcoma without clearly extending life, a trade-off weighed against its side effects.
ATP-competitive inhibitor of VEGFR1-3, PDGFRα/β, KIT, FGFR. Connects to VEGF / VEGFR and KIT.
1.Pazopanib slips into a pocket on VEGF / VEGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Generic pazopanib is available.
Multi-source generic on low-cost tiers; usually no prior authorisation. Cash prices without insurance are modest.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA215 · SMC advice: pazopanib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 2009 | Advanced renal cell carcinoma |
| US | 2012 | Advanced non-adipocytic soft-tissue sarcoma after chemotherapy |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Hypertension | 41% | 7% |
| Fatigue | 65% | 13% |
| ALT elevation | - | 8% |
| Pneumothorax | 3% | - |
PALETTE. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pazopanib" OR ABSTRACT:"Pazopanib" OR TITLE:"Votrient" OR ABSTRACT:"Votrient") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pazopanib, not a curated reading list.
Shares Retroperitoneal sarcoma, Angiosarcoma, Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), Leiomyosarcoma.
Shares Retroperitoneal sarcoma, Synovial sarcoma, Undifferentiated pleomorphic sarcoma (UPS), Leiomyosarcoma.
Shares Alveolar soft part sarcoma, Synovial sarcoma, Leiomyosarcoma, Anti-angiogenic therapy.
Shares Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302), Cediranib, Desmoplastic small round cell tumour, Alveolar soft part sarcoma.
Shares Retroperitoneal sarcoma, Leiomyosarcoma, Soft tissue sarcoma of the extremity (localised and advanced), Uterine sarcoma.
Shares Carotuximab, TAPPAS, Sarcomas (soft tissue, bone, GIST).
Shares Desmoplastic small round cell tumour, Dermatofibrosarcoma protuberans, The angiogenic switch & tumour vessels, KIT.
Shares Retroperitoneal sarcoma, Leiomyosarcoma, Soft tissue sarcoma of the extremity (localised and advanced), Sarcomas (soft tissue, bone, GIST).